11 results
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
12 Feb 24
Regulation FD Disclosure
4:15pm
that leads to chronic inflammation of the gastrointestinal tract. In addition, Celularity is continuing to investigate APPL-001 in muscle related conditions
424B3
CELU
Celularity Inc - Ordinary Shares
1 Jun 22
Prospectus supplement
4:06pm
of CYNK-001 showed evidence of significant killing against chronic myeloid leukemia, or CML, AML and MM, cell lines and primary AML samples. CYNK-001 … to commercialize and distribute Interfly and Centaflex within the United States in the field of acute and chronic non-healing wound care. On September
424B3
CELU
Celularity Inc - Ordinary Shares
3 May 22
Prospectus supplement
4:06pm
Preclinical studies of CYNK-001 showed evidence of significant killing against chronic myeloid leukemia, or CML, AML and MM, cell lines and primary AML … to commercialize and distribute Interfly and Centaflex within the United States in the field of acute and chronic non-healing wound care. On September 1, 2021, we
POS AM
h6pjf1iupjji
1 Apr 22
Prospectus update (post-effective amendment)
9:15pm
424B3
77sy 08khsvzb5uc3
12 Aug 21
Prospectus supplement
4:21pm
- Prev
- 1
- Next